<?xml version="1.0" encoding="UTF-8"?>
<rr:ResultsReport xmlns:rr="http://integration.foundationmedicine.com/reporting" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd">
  <rr:CustomerInformation>
    <rr:ReferenceID>01-2023-00030302</rr:ReferenceID>
    <rr:CSN />
    <rr:TRF>ORD-1650540-01</rr:TRF>
    <rr:MRN>49502321</rr:MRN>
    <rr:PhysicianId>109266</rr:PhysicianId>
    <rr:NPI />
  </rr:CustomerInformation>
  <rr:ResultsPayload>
    <FinalReport xmlns:xsd="http://www.w3.org/2001/XMLSchema" StagingId="1333837" clinicalId="1335184" xsi:noNamespaceSchemaLocation="http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd">
      <Application>
        <ApplicationSettings>
          <ApplicationSetting>
            <Name>Statement</Name>
            <Value />
          </ApplicationSetting>
        </ApplicationSettings>
      </Application>
      <DemographicCorrectionDate />
      <ReportId>ORD-1650540-01</ReportId>
      <SampleName>US1574415.01</SampleName>
      <Version>0</Version>
      <Sample>
        <FM_Id>ORD-1650540-01</FM_Id>
        <SampleId>US1574415.01</SampleId>
        <BlockId>HCC 8/31/1954</BlockId>
        <TRFNumber>ORD-1650540-01</TRFNumber>
        <TestType>FoundationOneLiquidDx</TestType>
        <SpecFormat>Tube Set</SpecFormat>
        <ReceivedDate>2023-06-13</ReceivedDate>
        <processSites>
          <processSite address="150 Second St., 1st Floor, Cambridge, MA 02141" cliaNumber="22D2027531" locationID="1" locationName="Cambridge" processID="1" processName="Extracted DNA" />
          <processSite address="150 Second St., 1st Floor, Cambridge, MA 02141" cliaNumber="22D2027531" locationID="1" locationName="Cambridge" processID="1" processName="LC" />
        </processSites>
      </Sample>
      <PMI>
        <ReportId>ORD-1650540-01</ReportId>
        <MRN>49502321</MRN>
        <FullName>Chien, Hsiu-Ching</FullName>
        <FirstName>Hsiu-Ching</FirstName>
        <LastName>Chien</LastName>
        <SubmittedDiagnosis>Unknown primary adenocarcinoma</SubmittedDiagnosis>
        <Gender>Female</Gender>
        <DOB>1954-08-31</DOB>
        <OrderingMD>Yeh, Yi-Chen</OrderingMD>
        <OrderingMDId>109266</OrderingMDId>
        <Pathologist>Not Provided</Pathologist>
        <CopiedPhysician1 />
        <MedFacilName>Taipei Veterans General Hospital</MedFacilName>
        <MedFacilID>205872</MedFacilID>
        <SpecSite>Blood</SpecSite>
        <CollDate>2023-06-08</CollDate>
        <ReceivedDate>2023-06-13</ReceivedDate>
        <CountryOfOrigin>TW</CountryOfOrigin>
      </PMI>
      <PertinentNegatives />
      <Summaries alterationCount="12" clinicalTrialCount="0" resistiveCount="0" sensitizingCount="0" />
      <VariantProperties>
        <VariantProperty geneName="ALOX12B" isVUS="true" variantName="D641N" />
        <VariantProperty geneName="MERTK" isVUS="true" variantName="N625S" />
        <VariantProperty geneName="MSH2" isVUS="true" variantName="I169V" />
        <VariantProperty geneName="NOTCH3" isVUS="true" variantName="P167S" />
        <VariantProperty geneName="PARP1" isVUS="true" variantName="S5W" />
        <VariantProperty geneName="PTCH1" isVUS="true" variantName="E44G,S827G" />
        <VariantProperty geneName="ROS1" isVUS="true" variantName="E1605Q" />
        <VariantProperty geneName="SDHA" isVUS="true" variantName="I247V" />
      </VariantProperties>
      <priorTests />
      <Genes>
        <Gene>
          <Name>Blood Tumor Mutational Burden</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>01</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="01" />
              </AlterationProperties>
              <Interpretation>Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide-based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Aggarwal et al., 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered. Average bTMB levels in solid tumors other than NSCLC have not been evaluated (PubMed, Mar 2023). Published data investigating the prognostic implications of TMB have mainly been investigated in the context of tissue TMB. In patients with NSCLC, increased TMB is associated with higher tumor grade and poor prognosis (Xiao et al., 2016; 27009843), as well as with a decreased frequency of known driver mutations in EGFR, ALK, ROS1, or MET (1% of high-TMB samples each), but not BRAF (10.3%) or KRAS (9.4%) (Spigel et al., 2016; ASCO Abstract 9017). Although some studies have reported a lack of association between smoking and increased TMB in NSCLC (Schwartz et al., 2016; ASCO Abstract 8533, Xiao et al., 2016; 27009843, Shim et al., 2015; 26200269), several other large studies did find a strong link (Govindan et al., 2012; 22980976, Ding et al., 2008; 18948947, Imielinski et al., 2012; 22980975, Kim et al., 2014; 24323028). In CRC, elevated TMB is associated with a higher frequency of BRAF V600E driver mutations (Cancer Genome Atlas Network, 2012; 22810696, Stadler et al., 2016; 27022117) and with microsatellite instability (MSI) (George et al., 2016; ASCO Abstract 3587, Nagahashi et al., 2016; ASCO Abstract e15103, Stadler et al., 2016; 27022117), which in turn has been reported to correlate with better prognosis (Samowitz et al., 2001; 11535541, Elsaleh and Iacopetta, 2001; 12445368, Brueckl et al., 2003; 12820457, Guidoboni et al., 2001; 11438476, Gryfe et al., 2000; 10631274, Sinicrope et al., 2006; 16952542, Guastadisegni et al., 2010; 20627535, Laghi and Malesci, 2012; 22722556). Although increased TMB is associated with increased tumor grade in endometrioid endometrial carcinoma (Mehnert et al., 2016; 27159395, Cancer Genome Atlas Research Network., 2013; 23636398, Hussein et al., 2015; 25394778, Church et al., 2013; 23528559) and bladder cancer (Cazier et al., 2016; 24777035), it is also linked with improved prognosis in patients with these tumor types (Rosenberg et al., 2016; ASCO Abstract 104, Cancer Genome Atlas Research Network., 2013; 23636398). On the basis of clinical evidence in solid tumors, increased blood tumor mutational burden (bTMB) may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1 (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Li et al., 2020; ASCO Abstract 6511, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti-PD-1 (Schenker et al., 2022; AACR Abstract CT022, Aggarwal et al., 2020; 32102950, Peters et al., 2019; AACR Abstract CT074, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti-PD-1/CTLA4 therapies (Schenker et al., 2022; AACR Abstract CT022, Saori et al., 2021; ESMO Abstract 80P), anti-PD-L1/CTLA4 therapies (Chen et al., 2020; 32379280, Loree et al., 2021; ASCO GI Abstract 61, Li et al., 2020; ASCO Abstract 6511, Rizvi et al., 2020; 32271377, Si et al., 2021; 33355200, Leighl et al., 2022; 34800700). A Phase 2 multi-solid-tumor trial showed that bTMB ≥16 Muts/Mb (as measured by this assay) was associated with improved survival from treatment with a PD-1 inhibitor alone or in combination with a CTLA-4 inhibitor (Schenker et al., 2022; AACR Abstract CT022). In non-small cell lung cancer (NSCLC), multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single-agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 Muts/Mb-16 Muts/Mb (Gandara et al., 2018; 30082870, Socinski et al., 2019 ESMO Abstract LBA83, Aggarwal et al. 2020; 32102950, Rizvi et al., 2020; 32271377, Si et al., 2021; 33355200, Leighl et al., 2022; 34800700). In head and neck squamous cell carcinoma (HNSCC), a Phase 3 trial showed that bTMB ≥16 Muts/Mb (approximate equivalency ≥8 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD-L1 inhibitor alone or in combination with a CTLA-4 inhibitor (Li et al., 2020; ASCO Abstract 6511). In colorectal cancer (CRC), a Phase 2 study showed that bTMB TMB ≥28 Muts/Mb (approximate equivalency ≥14 Muts/Mb as measured by this assay) was associated with improved OS from a PD-L1 inhibitor alone or in combination with a CTLA-4 inhibitor (Loree et al., 2021; ASCO GI Abstract 61, Chen et al., 2020; 32379280).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>Microsatellite status</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>Cannot Be Determined</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="Cannot Be Determined" />
              </AlterationProperties>
              <Interpretation>Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. MSI-high (MSI-H) has been observed at high frequency in endometrial cancers (14-33%)(Santin et al., ASCO 2016; Abstract 414, Zighelboim et al., 2007; 17513808, Hampel et al., 2006; 16885385, Stelloo et al., 2016; 27006490, Kanopiene et al., 2014; 25458958, Black et al., 2006; 16549821, Nout et al., 2012; 22609107, Steinbakk et al., 2011; 21547578, Bilbao et al., 2010; 20005452), colorectal cancers (CRCs; 10-15%)(Guastadisegni et al., 2010; 20627535, Pawlik et al., 2004; 15528785, Kocarnik et al., 2015; 26337942, Cancer Genome Atlas Network., 2012; 22810696, Lal et al., 2015; 25949894), and gastric cancers (12-35%)(Hiyama et al., 2004; 15209621, Wu et al., 1998; 9537253, dos Santos et al., 1996; 8536886, Fang et al., 2013; 23555086) and at lower frequencies in many other tumor types, including esophageal (Hall et al., 2016; ASCO Gastrointestinal Cancer Symposium Abstract 528, Farris et al., 2011; 21422910), small bowel (Gingras et al., 2015; AACR Pancreatic Cancer Abstract PR06, Agaramet al., 2010; 20395525, Ruemmele et al., 2009; 19252434, Planck et al., 2003; 12627520, Hibi et al., 1995; 7775257, Muneyuki et al., 2000; 11117578), hepatobiliary (Zhang et al., 2005; 15918185, Chiappini et al., 2004; 14656944, Suto et al., 2001; 11223838, Momoi et al., 2001; 11580146, Liengswangwong et al., 2003; 14506736, Moy et al., 2015; 25680569, Yoshida et al., 2000; 11063221), prostate (Cheng et al., 2016; Genitourinary Cancers Symposium Abstract 251, Pritchard et al., 2014; 25255306, Azzouzi et al., 2007; 17233803, Burger et al., 2006; 16924473), and urinary tract carcinomas (Harper et al., 2015; USCAP Abstract 905, Bai et al., 2013; 23690119, Giedl et al., 2014; 25319978, Yamamoto et al., 2006; 16675567). In one study, MSI-H status was associated with a positive prognostic effect in patients with gastric cancer treated with surgery alone and a negative predictive effect in patients treated with chemotherapy (Smyth et al., 2015; ASCO Gastrointestinal Cancers Symposium Abstract 62). Data regarding the role of MSI-H on prognosis and survival in endometrial cancer are conflicting (Zighelboim et al., 2007; 17513808, Kanopiene et al., 2014; 25458958, Bilbao-Sieyro et al., 2014; 25026289, Mackay et al., 2010; 20304627, Steinbakk et al., 2011; 21547578, Arabi et al., 2009; 19275958, Black et al., 2006; 16549821). However, studies specifically analyzing early stage endometrial cancer have reported a correlation between MSI-H and decreased survival (Stelloo et al., 2016; 27006490, Mackay et al., 2010; 20304627, Nout et al., 2012; 22609107, Bilbao et al., 2010; 20005452), thereby suggesting that MSI-H predicts for poor prognosis in this subset of endometrial tumors. On the basis of clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD-1-targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), retifanlimab, and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Shitara et al., 2022; 35322232, Andre et al., 2022; ASCO GI Abstract 244, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143, Berton et al., 2021; SITC Abstract 956), as well as PD-L1-targeting agents atezolizumab, avelumab, and durvalumab (alone or in combination with tremelimumab) (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92, Pietrantonio et al., 2023; ASCO GI Abstract 358, Lee et al., 2023; ASCO GI abstract 401, Rubinstein et al., 2022; 36512912, Marie et al., 2021; 33811152). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>Tumor Fraction</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>Elevated Tumor Fraction Not Detected</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="Elevated Tumor Fraction Not Detected" />
              </AlterationProperties>
              <Interpretation>Tumor fraction provides an estimate of the percentage of ctDNA present in a cell-free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single-nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content (Li et al., 2019; 31602320), the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy (Zhang et al., 2020; 32757294, Butler et al., 2019; 30833418). Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3) (Bettegowda et al., 2014; 24553385). Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer (Lapin et al., 2018; 30400802), Ewing sarcoma and osteosarcoma (Shulman et al., 2018; 30131550), prostate cancer (Choudhury et al., 2018; 30385733, Conteduca et al., 2019; ASCO abstract 5039), breast cancer (Stover et al., 2018; 29298117), leiomyosarcoma (Hemming et al., 2019; 30793095), esophageal cancer (Egyud et al., 2019; 31059681), colorectal cancer (Fan et al., 2017; 28187169), and gastrointestinal cancer (Vu et al., 2020; DOI: 10.1200/PO.19.00204). Specimens with elevated tumor fraction values have high circulating-tumor DNA (ctDNA) content, and thus higher sensitivity for identifying genomic alterations. Such specimens are at a lower risk of false negative results. However, if elevated tumor fraction is not detected, it does not exclude the presence of disease burden or compromise the confidence of reported alterations. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management (Bronkhorst et al., 2019; 30923679, Raja et al., 2018; 30093454, Hrebien et al., 2019; 30860573, Conteduca et al., 2019; ASCO Abstract 5039, Choudhury et al., 2018; 30385733, Goodall et al., 2017; 28450425, Goldberg et al., 2018; 29330207).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
      </Genes>
      <Trials />
      <References>
        <Reference number="0">
          <ReferenceId>31602320</ReferenceId>
          <FullCitation>Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="1">
          <ReferenceId>32757294</ReferenceId>
          <FullCitation>Zhang EW, et al. Cancer (2020) pmid: 32757294</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="2">
          <ReferenceId>30833418</ReferenceId>
          <FullCitation>Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="3">
          <ReferenceId>24553385</ReferenceId>
          <FullCitation>Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="4">
          <ReferenceId>30400802</ReferenceId>
          <FullCitation>Lapin M, et al. J Transl Med (2018) pmid: 30400802</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="5">
          <ReferenceId>30131550</ReferenceId>
          <FullCitation>Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="6">
          <ReferenceId>30385733</ReferenceId>
          <FullCitation>Choudhury AD, et al. JCI Insight (2018) pmid: 30385733</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="7">
          <ReferenceId>29298117</ReferenceId>
          <FullCitation>Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="8">
          <ReferenceId>30793095</ReferenceId>
          <FullCitation>Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="9">
          <ReferenceId>31059681</ReferenceId>
          <FullCitation>Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="10">
          <ReferenceId>28187169</ReferenceId>
          <FullCitation>Fan G, et al. PLoS ONE (2017) pmid: 28187169</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="11">
          <ReferenceId>30923679</ReferenceId>
          <FullCitation>Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="12">
          <ReferenceId>30093454</ReferenceId>
          <FullCitation>Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="13">
          <ReferenceId>30860573</ReferenceId>
          <FullCitation>Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="14">
          <ReferenceId>28450425</ReferenceId>
          <FullCitation>Goodall J, et al. Cancer Discov (2017) pmid: 28450425</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="15">
          <ReferenceId>29330207</ReferenceId>
          <FullCitation>Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="16">
          <ReferenceId>15748635</ReferenceId>
          <FullCitation>Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="17">
          <ReferenceId>23875803</ReferenceId>
          <FullCitation>Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="18">
          <ReferenceId>12379884</ReferenceId>
          <FullCitation>Pfeifer GP, et al. Oncogene (2002) pmid: 12379884</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="19">
          <ReferenceId>25765070</ReferenceId>
          <FullCitation>Rizvi NA, et al. Science (2015) pmid: 25765070</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="20">
          <ReferenceId>24336570</ReferenceId>
          <FullCitation>Johnson BE, et al. Science (2014) pmid: 24336570</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="21">
          <ReferenceId>29452419</ReferenceId>
          <FullCitation>Choi S, et al. Neuro-oncology (2018) pmid: 29452419</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="22">
          <ReferenceId>23636398</ReferenceId>
          <FullCitation>Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="23">
          <ReferenceId>23447401</ReferenceId>
          <FullCitation>Briggs S, et al. J. Pathol. (2013) pmid: 23447401</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="24">
          <ReferenceId>24583393</ReferenceId>
          <FullCitation>Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="25">
          <ReferenceId>22810696</ReferenceId>
          <FullCitation>Nature (2012) pmid: 22810696</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="26">
          <ReferenceId>25568919</ReferenceId>
          <FullCitation>Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="27">
          <ReferenceId>30082870</ReferenceId>
          <FullCitation>Gandara DR, et al. Nat. Med. (2018) pmid: 30082870</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="28">
          <ReferenceId>30816954</ReferenceId>
          <FullCitation>Wang Z, et al. JAMA Oncol (2019) pmid: 30816954</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="29">
          <ReferenceId>32102950</ReferenceId>
          <FullCitation>Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="30">
          <ReferenceId>27009843</ReferenceId>
          <FullCitation>Xiao D, et al. Oncotarget (2016) pmid: 27009843</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="31">
          <ReferenceId>26200269</ReferenceId>
          <FullCitation>Shim HS, et al. J Thorac Oncol (2015) pmid: 26200269</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="32">
          <ReferenceId>22980976</ReferenceId>
          <FullCitation>Govindan R, et al. Cell (2012) pmid: 22980976</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="33">
          <ReferenceId>18948947</ReferenceId>
          <FullCitation>Ding L, et al. Nature (2008) pmid: 18948947</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="34">
          <ReferenceId>22980975</ReferenceId>
          <FullCitation>Imielinski M, et al. Cell (2012) pmid: 22980975</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="35">
          <ReferenceId>24323028</ReferenceId>
          <FullCitation>Kim Y, et al. J. Clin. Oncol. (2014) pmid: 24323028</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="36">
          <ReferenceId>27022117</ReferenceId>
          <FullCitation>Stadler ZK, et al. J. Clin. Oncol. (2016) pmid: 27022117</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="37">
          <ReferenceId>11535541</ReferenceId>
          <FullCitation>Samowitz WS, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11535541</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="38">
          <ReferenceId>12445368</ReferenceId>
          <FullCitation>Elsaleh H, et al. Clin Colorectal Cancer (2001) pmid: 12445368</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="39">
          <ReferenceId>12820457</ReferenceId>
          <FullCitation>Brueckl WM, et al. Anticancer Res. () pmid: 12820457</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="40">
          <ReferenceId>11438476</ReferenceId>
          <FullCitation>Guidoboni M, et al. Am. J. Pathol. (2001) pmid: 11438476</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="41">
          <ReferenceId>10631274</ReferenceId>
          <FullCitation>Gryfe R, et al. N. Engl. J. Med. (2000) pmid: 10631274</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="42">
          <ReferenceId>16952542</ReferenceId>
          <FullCitation>Sinicrope FA, et al. Gastroenterology (2006) pmid: 16952542</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="43">
          <ReferenceId>20627535</ReferenceId>
          <FullCitation>Guastadisegni C, et al. Eur. J. Cancer (2010) pmid: 20627535</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="44">
          <ReferenceId>22722556</ReferenceId>
          <FullCitation>Laghi L, et al. Dig Dis (2012) pmid: 22722556</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="45">
          <ReferenceId>27159395</ReferenceId>
          <FullCitation>Mehnert JM, et al. J. Clin. Invest. (2016) pmid: 27159395</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="46">
          <ReferenceId>25394778</ReferenceId>
          <FullCitation>Hussein YR, et al. Mod. Pathol. (2015) pmid: 25394778</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="47">
          <ReferenceId>23528559</ReferenceId>
          <FullCitation>Church DN, et al. Hum. Mol. Genet. (2013) pmid: 23528559</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="48">
          <ReferenceId>24777035</ReferenceId>
          <FullCitation>Cazier JB, et al. Nat Commun (2014) pmid: 24777035</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="49">
          <ReferenceId>35274716</ReferenceId>
          <FullCitation>Sturgill EG, et al. Oncologist (2022) pmid: 35274716</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="50">
          <ReferenceId>32379280</ReferenceId>
          <FullCitation>Chen EX, et al. JAMA Oncol (2020) pmid: 32379280</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="51">
          <ReferenceId>32271377</ReferenceId>
          <FullCitation>Rizvi NA, et al. JAMA Oncol (2020) pmid: 32271377</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="52">
          <ReferenceId>33355200</ReferenceId>
          <FullCitation>Si H, et al. Clin Cancer Res (2021) pmid: 33355200</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="53">
          <ReferenceId>34800700</ReferenceId>
          <FullCitation>Leighl NB, et al. J Thorac Oncol (2022) pmid: 34800700</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="54">
          <ReferenceId>26337942</ReferenceId>
          <FullCitation>Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="55">
          <ReferenceId>21081928</ReferenceId>
          <FullCitation>You JF, et al. Br. J. Cancer (2010) pmid: 21081928</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="56">
          <ReferenceId>24623249</ReferenceId>
          <FullCitation>Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="57">
          <ReferenceId>17513808</ReferenceId>
          <FullCitation>Zighelboim I, et al. J. Clin. Oncol. (2007) pmid: 17513808</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="58">
          <ReferenceId>16885385</ReferenceId>
          <FullCitation>Hampel H, et al. Cancer Res. (2006) pmid: 16885385</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="59">
          <ReferenceId>27006490</ReferenceId>
          <FullCitation>Stelloo E, et al. Clin. Cancer Res. (2016) pmid: 27006490</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="60">
          <ReferenceId>25458958</ReferenceId>
          <FullCitation>Kanopienė D, et al. Medicina (Kaunas) (2014) pmid: 25458958</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="61">
          <ReferenceId>16549821</ReferenceId>
          <FullCitation>Black D, et al. J. Clin. Oncol. (2006) pmid: 16549821</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="62">
          <ReferenceId>22609107</ReferenceId>
          <FullCitation>Nout RA, et al. Gynecol. Oncol. (2012) pmid: 22609107</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="63">
          <ReferenceId>21547578</ReferenceId>
          <FullCitation>Steinbakk A, et al. Cell Oncol (Dordr) (2011) pmid: 21547578</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="64">
          <ReferenceId>20005452</ReferenceId>
          <FullCitation>Bilbao C, et al. Int. J. Radiat. Oncol. Biol. Phys. (2010) pmid: 20005452</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="65">
          <ReferenceId>15528785</ReferenceId>
          <FullCitation>Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="66">
          <ReferenceId>25949894</ReferenceId>
          <FullCitation>Lal N, et al. Oncoimmunology (2015) pmid: 25949894</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="67">
          <ReferenceId>15209621</ReferenceId>
          <FullCitation>Hiyama T, et al. J. Gastroenterol. Hepatol. (2004) pmid: 15209621</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="68">
          <ReferenceId>9537253</ReferenceId>
          <FullCitation>Wu MS, et al. Cancer Res. (1998) pmid: 9537253</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="69">
          <ReferenceId>8536886</ReferenceId>
          <FullCitation>dos Santos NR, et al. Gastroenterology (1996) pmid: 8536886</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="70">
          <ReferenceId>23555086</ReferenceId>
          <FullCitation>Fang WL, et al. Biomed Res Int (2013) pmid: 23555086</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="71">
          <ReferenceId>21422910</ReferenceId>
          <FullCitation>Farris AB, et al. Am. J. Surg. Pathol. (2011) pmid: 21422910</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="72">
          <ReferenceId>20395525</ReferenceId>
          <FullCitation>Agaram NP, et al. Am. J. Clin. Pathol. (2010) pmid: 20395525</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="73">
          <ReferenceId>19252434</ReferenceId>
          <FullCitation>Ruemmele P, et al. Am. J. Surg. Pathol. (2009) pmid: 19252434</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="74">
          <ReferenceId>12627520</ReferenceId>
          <FullCitation>Planck M, et al. Cancer (2003) pmid: 12627520</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="75">
          <ReferenceId>7775257</ReferenceId>
          <FullCitation>Hibi K, et al. Jpn. J. Cancer Res. (1995) pmid: 7775257</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="76">
          <ReferenceId>11117578</ReferenceId>
          <FullCitation>Muneyuki T, et al. Dig. Dis. Sci. (2000) pmid: 11117578</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="77">
          <ReferenceId>15918185</ReferenceId>
          <FullCitation>Zhang SH, et al. World J. Gastroenterol. (2005) pmid: 15918185</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="78">
          <ReferenceId>14656944</ReferenceId>
          <FullCitation>Chiappini F, et al. Carcinogenesis (2004) pmid: 14656944</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="79">
          <ReferenceId>11223838</ReferenceId>
          <FullCitation>Suto T, et al. J Surg Oncol (2001) pmid: 11223838</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="80">
          <ReferenceId>11580146</ReferenceId>
          <FullCitation>Momoi H, et al. J. Hepatol. (2001) pmid: 11580146</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="81">
          <ReferenceId>14506736</ReferenceId>
          <FullCitation>Liengswangwong U, et al. Int. J. Cancer (2003) pmid: 14506736</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="82">
          <ReferenceId>25680569</ReferenceId>
          <FullCitation>Moy AP, et al. Virchows Arch. (2015) pmid: 25680569</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="83">
          <ReferenceId>11063221</ReferenceId>
          <FullCitation>Yoshida T, et al. J. Gastroenterol. (2000) pmid: 11063221</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="84">
          <ReferenceId>25255306</ReferenceId>
          <FullCitation>Pritchard CC, et al. Nat Commun (2014) pmid: 25255306</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="85">
          <ReferenceId>17233803</ReferenceId>
          <FullCitation>Azzouzi AR, et al. BJU Int. (2007) pmid: 17233803</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="86">
          <ReferenceId>16924473</ReferenceId>
          <FullCitation>Burger M, et al. J. Mol. Med. (2006) pmid: 16924473</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="87">
          <ReferenceId>23690119</ReferenceId>
          <FullCitation>Bai S, et al. Am. J. Clin. Pathol. (2013) pmid: 23690119</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="88">
          <ReferenceId>25319978</ReferenceId>
          <FullCitation>Giedl J, et al. Am. J. Clin. Pathol. (2014) pmid: 25319978</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="89">
          <ReferenceId>16675567</ReferenceId>
          <FullCitation>Yamamoto Y, et al. Clin. Cancer Res. (2006) pmid: 16675567</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="90">
          <ReferenceId>25026289</ReferenceId>
          <FullCitation>Bilbao-Sieyro C, et al. Oncotarget (2014) pmid: 25026289</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="91">
          <ReferenceId>20304627</ReferenceId>
          <FullCitation>Mackay HJ, et al. Eur. J. Cancer (2010) pmid: 20304627</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="92">
          <ReferenceId>19275958</ReferenceId>
          <FullCitation>Arabi H, et al. Gynecol. Oncol. (2009) pmid: 19275958</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="93">
          <ReferenceId>17204026</ReferenceId>
          <FullCitation>Histopathology (2007) pmid: 17204026</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="94">
          <ReferenceId>28734759</ReferenceId>
          <FullCitation>Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="95">
          <ReferenceId>29355075</ReferenceId>
          <FullCitation>Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="96">
          <ReferenceId>35322232</ReferenceId>
          <FullCitation>Shitara K, et al. Nature (2022) pmid: 35322232</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="97">
          <ReferenceId>23169436</ReferenceId>
          <FullCitation>Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="98">
          <ReferenceId>26028255</ReferenceId>
          <FullCitation>Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="99">
          <ReferenceId>33001143</ReferenceId>
          <FullCitation>Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="100">
          <ReferenceId>36512912</ReferenceId>
          <FullCitation>Rubinstein MM, et al. Gynecol Oncol (2022) pmid: 36512912</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="101">
          <ReferenceId>33811152</ReferenceId>
          <FullCitation>Kanikarla Marie P, et al. Clin Cancer Res (2021) pmid: 33811152</FullCitation>
          <Include>true</Include>
        </Reference>
      </References>
      <Signatures>
        <Signature>
          <ServerTime>2023-06-20 16:00:37</ServerTime>
          <OpName>Douglas A. Mata, MD, MPH | Julia Elvin, M.D., Ph.D., Laboratory Director</OpName>
          <Text>Douglas A. Mata, MD, MPH | Julia Elvin, M.D., Ph.D., Laboratory Director</Text>
        </Signature>
      </Signatures>
      <reportProperties>
        <reportProperty identifier="QualityControlMetrics" key="MedianCoverageValue">
          <value>N/A</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="TumorMutationBurdenScore">
          <value>Units Not Reported</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="MicrosatelliteStatusScore">
          <value>0 fraction-unstable-loci</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="LossOfHeterozygosityScore">
          <value>Units Not Reported</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="BloodTumorMutationalBurdenScore">
          <value>1 Muts/Mb</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="TumorFractionScore">
          <value>0%</value>
        </reportProperty>
      </reportProperties>
      <comments />
      <AAC>
        <Amendmends />
      </AAC>
    </FinalReport>
    <variant-report xmlns="http://foundationmedicine.com/compbio/variant-report-external" disease-ontology="Unknown primary adenocarcinoma" flowcell-analysis="2000029582" gender="female" pathology-diagnosis="Adenocarcinoma" pipeline-version="v3.23.0" purity-assessment="4.82" specimen="ORD-1650540-01*US1574415.01" study="CLINICAL-F1LCDx" test-request="ORD-1650540-01" test-type="FoundationOneLiquidDx" tissue-of-origin="Blood" xsi:schemaLocation="http://foundationmedicine.com/compbio/variant-report-external http://integration.foundationmedicine.com/reporting/variant-report-external-2.2.xsd">
      <samples>
        <sample bait-set="AB1" name="SQ-US1574415.01-1" nucleic-acid-type="DNA" />
      </samples>
      <quality-control status="Pass" />
      <short-variants>
        <short-variant allele-fraction="0.5026" cds-effect="2479A&gt;G" depth="1910" equivocal="false" functional-effect="missense" gene="PTCH1" percent-reads="50.26" position="chr9:98229479" protein-effect="S827G" status="unknown" strand="-" transcript="NM_000264">
          <dna-evidence sample="SQ-US1574415.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.4751" cds-effect="14C&gt;G" depth="1126" equivocal="false" functional-effect="missense" gene="PARP1" percent-reads="47.51" position="chr1:226595617" protein-effect="S5W" status="unknown" strand="-" transcript="NM_001618">
          <dna-evidence sample="SQ-US1574415.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.5017" cds-effect="739A&gt;G" depth="1174" equivocal="false" functional-effect="missense" gene="SDHA" percent-reads="50.17" position="chr5:228417" protein-effect="I247V" status="unknown" strand="+" transcript="NM_004168">
          <dna-evidence sample="SQ-US1574415.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.5145" cds-effect="1874A&gt;G" depth="1211" equivocal="false" functional-effect="missense" gene="MERTK" percent-reads="51.45" position="chr2:112765966" protein-effect="N625S" status="unknown" strand="+" transcript="NM_006343">
          <dna-evidence sample="SQ-US1574415.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.5013" cds-effect="499C&gt;T" depth="1929" equivocal="false" functional-effect="missense" gene="NOTCH3" percent-reads="50.13" position="chr19:15302951" protein-effect="P167S" status="unknown" strand="-" transcript="NM_000435">
          <dna-evidence sample="SQ-US1574415.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.5019" cds-effect="505A&gt;G" depth="2062" equivocal="false" functional-effect="missense" gene="MSH2" percent-reads="50.19" position="chr2:47637371" protein-effect="I169V" status="unknown" strand="+" transcript="NM_000251">
          <dna-evidence sample="SQ-US1574415.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.518" cds-effect="4813G&gt;C" depth="1469" equivocal="false" functional-effect="missense" gene="ROS1" percent-reads="51.8" position="chr6:117662652" protein-effect="E1605Q" status="unknown" strand="-" transcript="NM_002944">
          <dna-evidence sample="SQ-US1574415.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.5109" cds-effect="131A&gt;G" depth="1012" equivocal="false" functional-effect="missense" gene="PTCH1" percent-reads="51.09" position="chr9:98278972" protein-effect="E44G" status="unknown" strand="-" transcript="NM_001083603">
          <dna-evidence sample="SQ-US1574415.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.0054" cds-effect="1921G&gt;A" depth="1306" equivocal="false" functional-effect="missense" gene="ALOX12B" percent-reads="0.54" position="chr17:7976471" protein-effect="D641N" status="unknown" strand="-" transcript="NM_001139">
          <dna-evidence sample="SQ-US1574415.01-1" />
        </short-variant>
      </short-variants>
      <copy-number-alterations />
      <rearrangements />
      <biomarkers>
        <microsatellite-instability status="MSS" />
        <tumor-mutation-burden score="1.26" status="low" unit="mutations-per-megabase" />
      </biomarkers>
      <non-human-content>
        <non-human organism="HHV-4" reads-per-million="42" status="unknown">
          <dna-evidence sample="SQ-US1574415.01-1" />
        </non-human>
        <non-human organism="HPV-16" reads-per-million="49" status="unknown">
          <dna-evidence sample="SQ-US1574415.01-1" />
        </non-human>
        <non-human organism="HHV-8" reads-per-million="19" status="unknown">
          <dna-evidence sample="SQ-US1574415.01-1" />
        </non-human>
      </non-human-content>
    </variant-report>
  </rr:ResultsPayload>
</rr:ResultsReport>
